Conditional power analysis of the DEBUT trial

Affiliations

¹ Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 102300, China.
² Tropical Clinical Trials Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
³ Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 102300, China. Electronic address: liwei@mrbc-nccd.com.

Comment

Yang Wang et al. Lancet. 2020.

. 2020 Feb 22;395(10224):560.

doi: 10.1016/S0140-6736(19)32530-9.

¹ Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 102300, China.
² Tropical Clinical Trials Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
³ Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 102300, China. Electronic address: liwei@mrbc-nccd.com.

No abstract available

Comment in

Conditional power analysis of the DEBUT trial - Authors' reply.
Rissanen TT, Kärkkäinen JM. Rissanen TT, et al. Lancet. 2020 Feb 22;395(10224):561. doi: 10.1016/S0140-6736(19)32508-5. Lancet. 2020. PMID: 32087786 No abstract available.

Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.
Rissanen TT, Uskela S, Eränen J, Mäntylä P, Olli A, Romppanen H, Siljander A, Pietilä M, Minkkinen MJ, Tervo J, Kärkkäinen JM; DEBUT trial investigators. Rissanen TT, et al. Lancet. 2019 Jul 20;394(10194):230-239. doi: 10.1016/S0140-6736(19)31126-2. Epub 2019 Jun 13. Lancet. 2019. PMID: 31204115 Clinical Trial.